<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563105</url>
  </required_header>
  <id_info>
    <org_study_id>900-0003</org_study_id>
    <nct_id>NCT03563105</nct_id>
  </id_info>
  <brief_title>Assessment of Circulatory Compromise With Ox-Imager Using a Vascular Occlusion Test Protocol</brief_title>
  <official_title>Assessment of Circulatory Compromise With Ox-Imager Using a Vascular Occlusion Test Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Modulated Imaging Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Modulated Imaging Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the performance of Modulated Imaging Inc.'s (MI)
      next generation Spatial Frequency Domain Imaging (SFDI) system to measure potential
      circulatory compromise.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to demonstrate the performance of Modulated Imaging Inc.'s
      (MI) next generation Spatial Frequency Domain Imaging (SFDI) system, &quot;The Ox-Imager Mini&quot;.
      Potential circulatory compromise will be imaged in healthy volunteers using both the subject
      and predicate devices (Ox-Imager CS) in a Vascular Occlusion Test (VOT) model. The VOT model
      is an established paradigm to introduce transient ischemia in skin and the the subjects will
      be imaged during this time. The primary endpoint will be to measure significant decrease in
      tissue oxygen saturation after occlusion for both predicate and subject devices.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">May 30, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Vascular Occlusion Test</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Significant decrease in StO2 during occlusion</measure>
    <time_frame>immediate</time_frame>
    <description>significant decrease in StO2 during occlusion</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Circulatory; Change</condition>
  <arm_group>
    <arm_group_label>Desaturation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vascular Occlusion Test</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Ox-Imager Mini (Desaturation)</intervention_name>
    <description>Vascular Occlusion Test</description>
    <arm_group_label>Desaturation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 18 years of age

        Exclusion Criteria:

          -  History of congestive heart failure

          -  Patients with existing wound or ulcer.

          -  Rheumatoid arthritis

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amaan Mazhar, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Modulated Imaging Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orange County Wound and Hyperbaric</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 8, 2018</study_first_submitted>
  <study_first_submitted_qc>June 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>June 18, 2018</last_update_submitted>
  <last_update_submitted_qc>June 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tissue oxygen saturation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

